Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026 (Novartis Press Release) - Oct 7, 2026 - "Late-breaking data from positive Phase III REMODEL-1/-2 trials will show efficacy and safety profile of remibrutinib in RMS; Novartis to hold virtual investor event highlighting REMODEL data and remibrutinib in MS; Phase III NEOS late-breaker will expand evidence for Kesimpta (ofatumumab) in pediatric MS, where current approved treatment options remain limited; New Kesimpta data from STHENOS study in treatment-naive relapsing MS and from KATHAROS breastfeeding study will be presented."
P3 data • P4 data • Immunology • Multiple Sclerosis
|